Alexandria Real Estate Equities, Inc.: Form 10-Q for the period ended Sep 30, 2024
Filed with the SEC on Oct 21, 2024 and accepted by EDGAR at Oct 21, 2024, 16:06 ET.
Management's discussion and analysis
As filed, 89,574 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Forward-looking statements
Certain information and statements included in this quarterly report on Form 10-Q, including, without limitation, statements
containing the words “forecast,” “guidance,” “goals,” “projects,” “estimates,” “anticipates,” “believes,” “expects,” “intends,” “may,” “plans,”
“seeks,” “should,” “targets,” or “will,” or the negative of those words or similar words, constitute “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Forward-looking statements involve inherent risks and uncertainties regarding events, conditions, and financial trends that
may affect our future plans of operations, business strategy, results of operations, and financial position. A number of important factors
could cause actual results to differ materially from those included within or contemplated by the forward-looking statements, including,
but not limited to, the following:
- Operating factors, such as a failure to operate our business successfully in comparison to market expectations or in
comparison to our competitors, our inability to obtain capital when desired or refinance debt maturities when desired, and/
or a failure to maintain our status as a REIT for federal tax purposes;
- Market and industry factors, such as adverse developments concerning the life science industry and/or our tenants;
- Government factors, such as any unfavorable effects resulting from federal, state, local, and/or foreign government
policies, laws, and/or funding levels;
- Global factors, such as negative economic, social, political, financial, credit market, banking conditions, and/or regional
armed hostilities; and
- Other factors, such as climate change, cyber intrusions, and/or changes in laws, regulations, and financial accounting
standards.
This list of risks and uncertainties is not exhaustive. Additional information regarding risk factors that may affect us is included
under Part I; “Item 1A. Risk factors”; and “Item 7. Management’s discussion and analysis of financial condition and results of
operations” in our annual report on Form 10-K for the year ended December 31, 2023 and under respective sections in this quarterly
report on Form 10-Q. Readers of this quarterly report on Form 10-Q should also read our other documents filed publicly with the SEC
for further discussion regarding such factors.
45
Overview
We are a Maryland corporation formed in October 1994 that has elected to be taxed as a REIT for federal income tax
purposes. Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500® company, is a best-in-class, mission-driven life science
REIT making a positive and lasting impact on the world. As the pioneer of the life science real estate niche with our founding in 1994,
Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative mega campuses in AAA life science
innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle,
and New York City. As of September 30, 2024, Alexandria has a total market capitalization of $33.1 billion and an asset base in North
America that includes 41.8 million RSF of operating properties, 5.3 million RSF of Class A/A+ properties undergoing construction, and
one committed near-term project expected to commence construction in the next two years. Alexandria has a longstanding and proven
track record of developing Class A/A+ properties clustered in mega campuses that provide our innovative tenants with highly dynamic
and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity,
efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science companies through our
venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base
that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.
As of September 30, 2024:
- Investment-grade or publicly traded large cap tenants represented 53% of our annual rental revenue;
- Approximately 96% of our leases (on an annual rental revenue basis) contained effective annual rent escalations
approximating 3% that were either fixed or indexed based on a consumer price index or other index;
- Approximately 93% of our leases (on an annual rental revenue basis) were triple net leases, which require tenants to pay
substantially all real estate taxes, insurance, utilities, repairs and maintenance, common area expenses, and other
operating expenses (including increases thereto) in addition to base rent;
- Approximately 92% of our leases (on an annual rental revenue basis) provided for the recapture of capital expenditures
(such as HVAC maintenance and/or replacement, roof replacement, and parking lot resurfacing) that we believe would
typically be borne by the landlord in traditional office leases; and
- 80% of our leasing activity during the last twelve months was generated from our existing tenant base.
Our primary business objective is to maximize long-term asset value and stockholder returns based on a multifaceted platform
of internal and external growth. A key element of our strategy is our unique focus on Class A/A+ properties located in collaborative
mega campuses in AAA life science innovation clusters. Our mega campuses are designed for scalability, offering our tenants a clear
path for growth, including through our future developments and redevelopments. Strategically located near top academic medical
institutions and equipped with curated amenities, services, and transit access, our mega campuses are designed to support our tenants
in attracting and retaining top talent, which we believe is a key driver of tenant demand for our properties. Our strategy also includes
drawing upon our deep and broad real estate and life science relationships in order to identify and attract new and leading tenants and
to source additional value-creation real estate.
Executive summary
Operating results
| Net income attributable to Alexandria’s common stockholders – diluted: | Three Months Ended September 30, 2024 | 2023 | Nine Months Ended September 30, 2024 | 2023 |
|---|---|---|---|---|
| In millions | $164.7 | $21.9 | $374.5 | $184.4 |
| Per share | $0.96 | $0.13 | $2.18 | $1.08 |
| Funds from operations attributable to Alexandria’s common stockholders – diluted, as adjusted: | ||||
| In millions | $407.9 | $386.4 | $1,217.3 | $1,142.5 |
| Per share | $2.37 | $2.26 | $7.08 | $6.69 |
For additional information, refer to “Funds from operations and funds from operations, as adjusted, attributable to Alexandria
Real Estate Equities, Inc.’s common stockholders” under “Definitions and reconciliations” and to the tabular presentation of these items
in “Results of operations” in Item 2.
46
Continued operational excellence and solid results amid challenging macroeconomics environment
| (As of September 30, 2024, unless stated otherwise) | ||
|---|---|---|
| Occupancy of operating properties in North America | 94.7% | |
| Percentage of annual rental revenue in effect from mega campuses | 76% | |
| Percentage of annual rental revenue in effect from investment-grade or publicly traded large cap tenants | 53% | |
| Adjusted EBITDA margin for the three months ended September 30, 2024 | 70% | |
| Percentage of leases containing annual rent escalations | 96% | |
| Weighted-average remaining lease term: | ||
| Top 20 tenants | 9.5 | years |
| All tenants | 7.5 | years |
| Sustained strength in tenant collections: | ||
| Tenant receivables as a percentage of rental revenues for the three months ended September 30, 2024 | 0.9% | |
| October 2024 tenant rents and receivables collected as of the date of this report | 99.6% | |
| Tenant rents and receivables for the three months ended September 30, 2024 collected as of the date of this report | 99.9% |
Strong and flexible balance sheet with significant liquidity; top 10% credit rating ranking among all publicly traded U.S. REITs
- As of September 30, 2024, our credit ratings from Moody’s Ratings and S&P Global Ratings were Baa1 and BBB+,
respectively, which rank in the top 10% among all publicly traded U.S. REITs.
- Net debt and preferred stock to Adjusted EBITDA of 5.5x and fixed-charge coverage ratio of 4.4x for the three months ended
September 30, 2024 annualized.
- Significant liquidity of $5.4 billion.
- 31% of our total debt matures in 2049 and beyond.
- 12.6 years weighted-average remaining term of debt.
- Since 2020, an average of 97.7% of our debt has been fixed rate.
- Total debt and preferred stock to gross assets of 29%.
- $1.0 billion of capital contribution commitments from existing consolidated real estate joint venture partners to fund
construction from October 1, 2024 through 2027.
Strong leasing volume and solid rental rates
- Strong leasing volume aggregating 1.5 million RSF for the three months ended September 30, 2024, up 48% compared to our
previous four-quarter average of 1.0 million RSF.
- Rental rate changes on lease renewals and re-leasing of space were 5.1% and 1.5% (cash basis) for the three months ended
September 30, 2024 and 16.4% and 8.9% (cash basis) for the nine months ended September 30, 2024.
- 80% of our leasing activity during the last twelve months was generated from our existing tenant base.
| September 30, 2024 Three Months Ended | Nine Months Ended | ||
|---|---|---|---|
| Total leasing activity – RSF | 1,486,097 | 3,742,955 | |
| Leasing of development and redevelopment space – RSF | 39,121 | 480,342 | |
| Lease renewals and re-leasing of space: | |||
| RSF (included in total leasing activity above) | 1,278,857 | 2,863,277 | |
| Rental rate changes | 5.1% | (1) | 16.4% |
| Rental rate changes (cash basis) | 1.5% | (1) | 8.9% |
(1) Includes a five-year lease extension to an investment-grade rated technology tenant aggregating 357,136 RSF of recently acquired tech R&D space in our
Texas market that was renewed with rental rate changes of (33.6)% and (4.8)% (cash basis). These spaces were originally targeted for a future change in
use at acquisition, but we instead renewed them with a lower capital investment while we continue to evaluate options to convert these spaces in the future,
subject to market conditions. Excluding this lease, rental rate changes for renewed/re-leased space for the three months ended September 30, 2024 were
13.0% and 2.3% (cash basis).
47
Continued solid net operating income and internal growth
- Total revenue growth
- $791.6 million, up 10.9%, for the three months ended September 30, 2024, compared to $713.8 million for the three
months ended September 30, 2023.
- $2.3 billion, up 9.3%, for the nine months ended September 30, 2024, compared to $2.1 billion for the nine months ended
September 30, 2023.
- Net operating income (cash basis) of $2.0 billion for the three months ended September 30, 2024 annualized, increased by
$274.2 million, or 15.5%, compared to the three months ended September 30, 2023 annualized. Refer to “Net operating
income, net operating income (cash basis), and operating margin” under “Definitions and reconciliations” in Item 2 for a
reconciliation of our net income to net operating income (cash basis).
- Same property net operating income growth
- 1.5% and 6.5% (cash basis) for the three months ended September 30, 2024, compared to the three months ended
September 30, 2023.
- 1.6% and 4.6% (cash basis) for the nine months ended September 30, 2024, compared to the nine months ended
September 30, 2023.
- 96% of our leases contain contractual annual rent escalations approximating 3%.
Attractive dividend strategy to share net cash flows from operating activities with stockholders while retaining a significant portion for
reinvestment
- Common stock dividend declared for the three months ended September 30, 2024 of $1.30 per common share aggregating
$5.14 per common share for the twelve months ended September 30, 2024, up 24 cents, or 5%, over the twelve months
ended September 30, 2023.
- Dividend yield of 4.4% as of September 30, 2024.
- Dividend payout ratio of 55% for the three months ended September 30, 2024.
- Average annual dividend per-share growth of 5.4% from 2020 through the three months ended September 30, 2024
annualized.
- Significant net cash flows from operating activities after dividends retained for reinvestment aggregating $2.1 billion for the
years ended December 31, 2020 through 2023 and including the midpoint of our 2024 guidance range for net cash provided
by operating activities after dividends.
Ongoing successful execution of Alexandria’s 2024 capital strategy
We expect to continue pursuing our strategy to fund a significant portion of our capital requirements for the year ending
December 31, 2024 with dispositions primarily focused on sales of properties and land parcels not integral to our mega campus
strategy. Refer to “Dispositions” in Item 2 for additional details.
(in millions)
| Completed dispositions of 100% interest in properties | $319 |
| Pending dispositions subject to non-refundable deposits | 577 |
| Pending dispositions subject to executed letters of intent and/or purchase and sale agreement | 603 |
| Forward equity sales agreements | 28 |
| Total | $1,527 |
| 2024 guidance midpoint for dispositions and common equity | $1,550 |
- In September 2024, we completed the following transactions with our longstanding tenant, Fred Hutchinson Cancer Center
(“Fred Hutch”), in the Lake Union submarket:
- Sale of 1165 Eastlake Avenue East, a fully leased 100,086 RSF single-tenant Class A+ life science facility that was
developed in 2021. We sold the property for $150.0 million, or $1,499 per RSF, at strong capitalization rates of 4.7% and
4.9% (cash basis). Upon completion of the sale, we recognized a gain on sale of real estate aggregating $21.5 million.
- Fred Hutch executed early renewals aggregating 117,479 RSF at our 1201 and 1208 Eastlake Avenue East properties,
including a 15-year lease extension at 1201 Eastlake Avenue East.
- Our prior joint venture partner sold its ownership interest in each of 1201 and 1208 Eastlake Avenue East to Fred Hutch.
Our ownership interest in both properties remains unchanged at 30.0%. This sale, lease extensions, and new joint venture
affirm Fred Hutch’s commitment to South Lake Union.
48
Strong balance sheet management
Key capital metrics as of or for the three months ended September 30, 2024
| September 30, 2024 Quarter Annualized | Trailing 12 Months | Target for Fourth Quarter of 2024 Annualized | |
|---|---|---|---|
| Net debt and preferred stock to Adjusted EBITDA | 5.5x | 5.6x | Less than or equal to 5.1x |
| Fixed-charge coverage ratio | 4.4x | 4.5x | Greater than or equal to 4.5x |
- $33.1 billion in total market capitalization.
- $20.5 billion in total equity capitalization, which ranks in the top 10% among all publicly traded U.S. REITs.
- As of September 30, 2024, our non-real estate investments aggregated $1.5 billion:
- Unrealized gains presented in our consolidated balance sheet were $166.2 million, comprising gross unrealized gains and
losses aggregating $284.4 million and $118.2 million, respectively.
- Investment income of $15.2 million for the three months ended September 30, 2024 presented in our consolidated statement
of operations consisted of $23.0 million of realized gains and $2.6 million of unrealized gains, offset by $10.3 million of
impairment charges. Investment income of $14.9 million for the nine months ended September 30, 2024 presented in our
consolidated statement of operations consisted of $85.2 million of realized gains and $32.5 million of unrealized losses, offset
by $37.8 million of impairment charges.
Key capital events
- In September 2024, we amended and restated our unsecured senior line of credit to, among other changes, extend the
maturity date from January 22, 2028 to January 22, 2030, including extension options that we control.
- During the three months ended September 30, 2024, we had no activity under our ATM program. As of the date of this report,
the remaining aggregate amount available for future sales of common stock was $1.47 billion.
External growth and investments in real estate
Alexandria’s development and redevelopment pipeline delivered incremental annual net operating income of $21 million, commencing
during the three months ended September 30, 2024, and is expected to deliver incremental annual net operating income aggregating
$510 million primarily by the first quarter of 2028
- During the three months ended September 30, 2024, we placed into service development and redevelopment projects
aggregating 316,691 RSF that are 100% leased across multiple submarkets and delivered incremental annual net operating
income of $21 million. Deliveries during the three months ended September 30, 2024 included 250,000 RSF at 9820
Darnestown Road on the Alexandria Center® for Life Science – Shady Grove mega campus in our Rockville submarket.
- Annual net operating income (cash basis) is expected to increase by $57 million upon the burn-off of initial free rent, with a
weighted-average burn-off period of approximately six months, from recently delivered projects.
- 69% of the RSF in our total development and redevelopment pipeline is within our mega campuses.
(dollars in millions)
| Development and Redevelopment Projects Placed into service: | Incremental Annual Net Operating Income | RSF | Leased/ Negotiating Percentage | ||
|---|---|---|---|---|---|
| Six months ended June 30, 2024 | $42 | 628,427 | 100% | ||
| Three months ended September 30, 2024 | 21 | 316,691 | 100 | ||
| Total placed into service during nine months ended September 30, 2024 | $63 | 945,118 | 100% | ||
| Expected to be placed into service(1): | |||||
| Fourth quarter of 2024 through fourth quarter of 2025 | $158 | (2) | 5,467,897 | 55% | |
| First quarter of 2026 through first quarter of 2028 | 352 | (3) | |||
| $510 |
(1) Represents expected incremental annual net operating income to be placed into service from deliveries of projects undergoing construction and one committed
near-term project expected to commence construction in the next two years.
(2) Includes (i) 1.0 million RSF that is expected to stabilize through 2025 and is 92% leased/negotiating and (ii) expected partial deliveries through fourth quarter of
2025 from projects expected to stabilize in 2026 and beyond. Refer to the initial and stabilized occupancy years under “New Class A/A+ development and
redevelopment properties: current projects” in Item 2 for additional details.
(3) 70% of the leased RSF of our development and redevelopment projects was generated from our existing tenant base.
49
50
Operating summary
Same Property Net Operating Income Growth Rental Rate Growth: Renewed/Re-Leased Space
Margins(1) Favorable Lease Structure(2)
Operating Adjusted EBITDA Strategic Lease Structure by Owner and Operator of Collaborative Mega Campuses
71% 70% Increasing cash flows
Percentage of leases containing annual rent escalations 96%
Stable cash flows
Weighted-Average Lease Term of Executed Leases(3) Percentage of triple net leases 93%
Lower capex burden
8.8 years Percentage of leases providing for the recapture of capital expenditures 92%
Net Debt and Preferred Stock to Adjusted EBITDA(4) Fixed-Charge Coverage Ratio(4)
Refer to “Same properties” and “Definitions and reconciliations” in Item 2 for additional details. “Definitions and reconciliations” contains the definitions of “Fixed-charge
coverage ratio,” “Net debt and preferred stock to Adjusted EBITDA,” and “Net operating income” and their respective reconciliations from the most directly comparable
financial measures presented in accordance with GAAP.
(1) For the three months ended September 30, 2024.
(2) Percentages calculated based on our annual rental revenue in effect as of September 30, 2024.
(3) Represents the weighted-average lease term of executed leases based on annual rental revenue for the 10-year period from December 31, 2015 through September 30,
(4) Quarter annualized.
51
| Stable Cash Flows From Our High-Quality and Diverse Mix of Approximately 800 Tenants | |
|---|---|
| Investment-Grade or Publicly Traded Large Cap Tenants | |
| 92% | |
| of ARE’s Top 20 Tenant Annual Rental Revenue | |
| 53% | |
| of ARE’s Annual Rental Revenue | |
| Percentage of ARE’s Annual Rental Revenue | |
| Solid Historical Occupancy of 96% Over Past 10 Years(2) From Historically Strong Demand for Our Class A/A+ Properties in AAA Locations | |
| Mega Campuses | Occupancy Across Key Locations |
| Percentage of ARE’s Annual Rental Revenue |
(3)
Life Science
Product,
Service, and
Device
Multinational
Pharmaceutical
Public
Biotechnology –
Approved or
Marketed
Product
Public
Biotechnology –
Preclinical or
Clinical Stage
Private
Biotechnology
Other(1)
Other Investment-Grade
or Large Cap Tech
Biomedical and
Government
Institutions
76%
Mega
Campuses
24%
Non-Mega
Campuses
As of September 30, 2024. Annual rental revenue represents amounts in effect as of September 30, 2024. Refer to “Definitions and reconciliations” in Item 2 for additional
information.
(1) Represents the percentage of our annual rental revenue generated by technology, professional services, finance, telecommunications, and construction/real estate
companies, as well as retail-related tenants, which generate less than 1.0% of our annual rental revenue.
(2) Represents average occupancy of operating properties as of each December 31 from 2015 through 2023 and as of September 30, 2024.
(3) Refer to footnote 1 under “Summary of occupancy percentages in North America” in Item 2 for additional details.
52
Long-Duration and Stable Cash Flows From High-Quality and Diverse Tenants
Long-Duration Lease Terms
9.5 Years
Top 20 Tenants
7.5 Years
All Tenants
Weighted-Average Remaining Term(1)
Sustained Strength in Tenant Collections(2)
99.9%
For the Three Months Ended September 30, 2024
99.6%
October 2024
(1) Based on annual rental revenue in effect as of September 30, 2024.
(2) Represents the portion of total receivables billed for each period collected through the date of this report.
53
Leasing Activity
The following table summarizes our leasing activity at our properties:
| (Dollars per RSF) Leasing activity: Renewed/re-leased space(1) | Three Months Ended September 30, 2024 Including Straight-Line Rent | Cash Basis | Nine Months Ended September 30, 2024 Including Straight-Line Rent | Cash Basis | Year Ended December 31, 2023 Including Straight-Line Rent | Cash Basis | |||
|---|---|---|---|---|---|---|---|---|---|
| Rental rate changes | 5.1% | (2) | 1.5% | (2) | 16.4% | 8.9% | 29.4% | 15.8% | |
| New rates | $56.60 | $55.77 | $63.43 | $62.39 | $52.35 | $50.82 | |||
| Expiring rates | $53.86 | $54.95 | $54.47 | $57.28 | $40.46 | $43.87 | |||
| RSF | 1,278,857 | 2,863,277 | 3,046,386 | ||||||
| Tenant improvements/ leasing commissions | $43.73 | (3) | $33.92 | $26.09 | |||||
| Weighted-average lease term | 9.7 years | 8.7 years | 8.7 years | ||||||
| Developed/redeveloped/ previously vacant space leased(4) | |||||||||
| New rates | $52.66 | $52.18 | $64.59 | $62.90 | $65.66 | $59.74 | |||
| RSF | 207,240 | 879,678 | (5) | 1,259,686 | |||||
| Weighted-average lease term | 10.6 years | 8.1 years | 13.8 years | ||||||
| Leasing activity summary (totals): | |||||||||
| New rates | $56.05 | $55.27 | $63.69 | $62.50 | $56.09 | $53.33 | |||
| RSF | 1,486,097 | 3,742,955 | 4,306,072 | ||||||
| Weighted-average lease term | 9.8 years | 8.6 years | 11.3 years | ||||||
| Lease expirations(1) | |||||||||
| Expiring rates | $51.62 | $53.17 | $52.01 | $54.40 | $43.84 | $45.20 | |||
| RSF | 1,500,213 | 3,801,559 | 5,027,773 |
Leasing activity includes 100% of results for properties in North America in which we have an investment.
(1) Excludes month-to-month leases aggregating 355,698 RSF and 86,092 RSF as of September 30, 2024 and December 31, 2023, respectively. Month-to-month leases
aggregating 355,698 RSF as of September 30, 2024 include 226,144 RSF in our University Town Center submarket primarily related to space being temporarily held over
by an expiring tenant at buildings that are targeted for the future development of laboratory space, subject to market conditions and leasing. During the trailing twelve
months ended September 30, 2024, we granted free rent concessions averaging 0.7 months per annum.
(2) Includes a five-year lease extension to an investment-grade rated technology tenant aggregating 357,136 RSF of recently acquired tech R&D space in our Texas market
that was renewed with rental rate changes of (33.6)% and (4.8)% (cash basis). These spaces were originally targeted for a future change in use at acquisition, but we
instead renewed them with a lower capital investment while we continue to evaluate options to convert these spaces in the future, subject to market conditions. Excluding
this lease, rental rate changes for renewed/re-leased space were 13.0% and 2.3% (cash basis) for three months ended September 30, 2024. Rental rate changes may
experience volatility from quarter to quarter based on the volume and mix of leases executed. Refer to “Projected results” in Item 2 for rental rate changes expected from
leases executed for the year ending December 31, 2024.
(3) Includes tenant improvements and leasing commissions related to a 10.5-year extension of a recently acquired lease aggregating 85,019 RSF in our Fenway submarket
to an investment-grade rated academic institution. Excluding this lease, tenant improvements and leasing commissions per RSF for the three and nine months ended
September 30, 2024 were $33.16 and $28.85, respectively, which are consistent with the five-year quarterly average of $32.17 per RSF.
(4) Refer to “New Class A/A+ development and redevelopment properties: summary of pipeline” in Item 2 for additional information, including total project costs.
(5) Includes the five-year extension of 171,102 RSF at our 4155 Campus Point Court property in San Diego, a fully leased development project expected to deliver during the
fourth quarter of 2024.
54
Summary of contractual lease expirations
The following table summarizes the contractual lease expirations at our properties as of September 30, 2024:
| Year | RSF | Percentage of Occupied RSF | Annual Rental Revenue (per RSF)(1) | Percentage of Annual Rental Revenue |
|---|---|---|---|---|
| 2024 (2) | 518,665 | 1.4% | $69.19 | 1.7% |
| 2025 | 3,785,573 | 10.0% | $49.64 | 8.8% |
| 2026 | 2,714,170 | 7.1% | $53.21 | 6.7% |
| 2027 | 3,242,737 | 8.5% | $51.87 | 7.9% |
| 2028 | 4,332,150 | 11.4% | $51.78 | 10.5% |
| 2029 | 2,437,921 | 6.4% | $51.25 | 5.8% |
| 2030 | 3,135,445 | 8.3% | $43.25 | 6.3% |
| 2031 | 3,425,338 | 9.0% | $55.11 | 8.8% |
| 2032 | 1,093,311 | 2.9% | $59.53 | 3.0% |
| 2033 | 2,772,455 | 7.3% | $50.81 | 6.6% |
| Thereafter | 10,541,840 | 27.7% | $68.66 | 33.9% |
Contractual lease expirations at properties classified as held for sale as of September 30, 2024 are excluded from the information on this page.
(1) Represents amounts in effect as of September 30, 2024.
(2) Excludes month-to-month leases aggregating 355,698 RSF as of September 30, 2024.
55
The following tables present our lease expirations by market for the remainder of 2024 and for 2025 as of September 30,
2024:
| Market | 2024 Contractual Lease Expirations (in RSF) Leased Negotiating/ Anticipating Targeted for Future Development/Redevelopment(1) Remaining Expiring Leases Committed Near-Term/ Priority Anticipated Future | Total(2) | Annual Rental Revenue (per RSF)(3) | |
|---|---|---|---|---|
| Greater Boston | 73,614 21,621 — 104,500 80,788 | (4) | 280,523 | $86.07 |
| San Francisco Bay Area | 12,847 13,943 107,250 — 14,682 | 148,722 | 49.58 | |
| San Diego | 27,119 — — — 17,408 | 44,527 | 55.30 | |
| Seattle | — — — — 3,652 | 3,652 | N/A | |
| Maryland | — — — — 182 | 182 | N/A | |
| Research Triangle | 10,478 — — — 8,202 | 18,680 | 28.31 | |
| New York City | — — — — 9,058 | 9,058 | 109.57 | |
| Texas | — — — — — | — | — | |
| Canada | 13,321 — — — — | 13,321 | 26.54 | |
| Non-cluster/other markets | — — — — — | — | — | |
| Total | 137,379 35,564 107,250 104,500 133,972 | 518,665 | $69.19 | |
| Percentage of expiring leases | 26% 7% 21% 20% 26% | 100% | ||
| 2025 Contractual Lease Expirations (in RSF) | Annual Rental Revenue (per RSF)(3) | |||
| Market | Leased Negotiating/ Anticipating Targeted for Future Development/ Redevelopment(1) Remaining Expiring Leases(5) Total | |||
| Greater Boston | 172,446 145,715 25,312 659,355 (4) 1,002,828 | $76.13 | ||
| San Francisco Bay Area | 72,162 247,827 — 547,092 867,081 | 51.33 | ||
| San Diego | 83,546 — 269,048 260,627 613,221 | 22.98 | ||
| Seattle | — — — 196,419 196,419 | 25.10 | ||
| Maryland | 35,055 6,926 — 151,958 193,939 | 27.51 | ||
| Research Triangle | — — — 306,916 306,916 | 51.16 | ||
| New York City | — 13,273 — 54,966 68,239 | 105.86 | ||
| Texas | — — 198,972 247,246 446,218 | 40.09 | ||
| Canada | — — — 88,412 88,412 | 20.28 | ||
| Non-cluster/other markets | — — — 2,300 2,300 | 40.17 | ||
| Total | 363,209 413,741 493,332 2,515,291 3,785,573 | $49.64 | ||
| Percentage of expiring leases | 10% 11% 13% 66% 100% |
Contractual lease expirations at properties classified as held for sale as of September 30, 2024 are excluded from the information on this page.
(1) Primarily represents assets that were recently acquired for future development and redevelopment opportunities, for which we expect, subject to market conditions and
leasing, to commence first-time conversion from non-laboratory space to laboratory space, or to commence future ground-up development. As of September 30, 2024,
annual rental revenue from these leases expiring in 2024, including 226,144 RSF of month-to-month leases in our University Town Center submarket primarily related to
space being temporarily held over by an expiring tenant, and 2025 is $20.9 million and $17.5 million, respectively. The weighted-average expiration date of these leases
expiring in 2024 and 2025 is October 20, 2024 and January 10, 2025, respectively. Refer to “Investments in real estate” under “Definitions and reconciliations” in Item 2
for additional details, including development and redevelopment square feet currently included in rental properties.
(2) Excludes month-to-month leases aggregating 355,698 RSF as of September 30, 2024. Refer to “Leasing Activity” in Item 2 for additional details.
(3) Represents amounts in effect as of September 30, 2024.
(4) Includes 41,908 RSF and 210,868 RSF expiring in 2024 and 2025, respectively, related to properties that are under executed letters of intent and/or purchase and sale
agreements to sell. Approximately 95% of the 2025 remaining expiring leases in Greater Boston are located in our Cambridge/Inner Suburbs submarket. Refer to
footnote 5 for additional details.
(5) Includes 768,080 RSF in four submarkets with a weighted-average expiration date of January 21, 2025 and annual rental revenue aggregating approximately
$47 million, with our share of this annual rental revenue aggregating $35 million, comprising the following: (i) existing laboratory spaces for which we are evaluating
options to re-lease or reposition from single tenancy to multi-tenancy that will remain in our same property pool at Alexandria Technology Square® in our Cambridge
submarket for 182,054 RSF and at 409 Illinois Street, where we have an ownership interest of 25.0%, in our Mission Bay submarket for 234,249 RSF (we are in early
discussions with a tenant to lease approximately 50% of this space); and (ii) non-laboratory space for which we are evaluating options to re-lease generally in their
current condition, reposition, or, subject to market conditions, may undergo a conversion through redevelopment in our Austin submarket for 247,246 RSF and in our
Research Triangle market for 104,531 RSF. Should we commence redevelopment efforts, these properties would be placed into our active pipeline and removed from
our same property pool; otherwise, they would remain in our same property pool. We expect downtime on the 768,080 RSF to range from 12 to 24 months on a
weighted-average basis.
56
Top 20 tenants
92% of Top 20 Tenant Annual Rental Revenue Is From Investment-Grade
or Publicly Traded Large Cap Tenants(1)
Our properties are leased to a high-quality and diverse group of tenants, with no individual tenant accounting for more than 5.8%
of our annual rental revenue in effect as of September 30, 2024. The following table sets forth information regarding leases with our 20
largest tenants in North America based upon annual rental revenue in effect as of September 30, 2024 (dollars in thousands, except
average market cap amounts):
| Tenant | Remaining Lease Term(1) (in Years) | Aggregate RSF Moody’s | Annual Rental Revenue(1) S&P | Percentage of Annual Rental Revenue (1) | Investment-Grade Credit Ratings | Average Market Cap (in billions) | |||
|---|---|---|---|---|---|---|---|---|---|
| 1 | Moderna, Inc. | 12.6 | 1,385,678 | $127,387 | 5.8% | — | — | $38.6 | |
| 2 | Eli Lilly and Company | 8.2 | 1,166,754 | 94,814 | 4.3 | A1 | A+ | $712.4 | |
| 3 | Bristol-Myers Squibb Company | 6.4 | 999,379 | 76,363 | 3.5 | A2 | A | $99.1 | |
| 4 | Takeda Pharmaceutical Company Limited | 10.7 | 549,759 | 47,899 | 2.2 | Baa1 | BBB+ | $44.5 | |
| 5 | Roche | 6.7 | 770,279 | 47,104 | 2.2 | Aa2 | AA | $227.8 | |
| 6 | Illumina, Inc. | 7.4 | 857,967 | 35,362 | 1.6 | Baa3 | BBB | $19.7 | |
| 7 | Alphabet Inc. | 3.1 | 625,015 | 34,899 | 1.6 | Aa2 | AA+ | $1,916.3 | |
| 8 | 2seventy bio, Inc.(2) | 8.9 | 312,805 | 33,543 | 1.5 | — | — | $0.2 | |
| 9 | Novartis AG | 3.8 | 450,664 | 30,969 | 1.4 | Aa3 | AA- | $231.8 | |
| 10 | United States Government | 5.9 | 429,359 | 28,593 | 1.3 | Aaa | AA+ | $— | |
| 11 | Cloud Software Group, Inc. | 2.4 | (3) | 292,013 | 28,537 | 1.3 | — | — | $— |
| 12 | Uber Technologies, Inc. | 58.0 | (4) | 1,009,188 | 27,776 | 1.3 | Baa2 | BBB- | $137.1 |
| 13 | AstraZeneca PLC | 5.1 | 450,848 | 27,156 | 1.2 | A2 | A+ | $222.8 | |
| 14 | Harvard University | 7.2 | 343,858 | 27,084 | 1.2 | Aaa | AAA | $— | |
| 15 | The Regents of the University of California | 6.6 | 372,647 | 23,670 | 1.1 | Aa2 | AA | $— | |
| 16 | Sanofi | 6.3 | 267,278 | 21,444 | 1.0 | A1 | AA | $126.6 | |
| 17 | Merck & Co., Inc. | 8.8 | 337,703 | 21,401 | 1.0 | A1 | A+ | $300.8 | |
| 18 | Amgen Inc. | 8.3 | 428,227 | 21,314 | 1.0 | Baa1 | BBB+ | $159.2 | |
| 19 | New York University | 7.4 | 218,983 | 21,056 | 1.0 | Aa2 | AA- | $— | |
| 20 | Massachusetts Institute of Technology | 4.7 | 246,725 | 20,527 | 0.9 | Aaa | AAA | $— | |
| Total/weighted-average | 9.5 | (4) | 11,515,129 | $796,898 | 36.4% |
Annual rental revenue and RSF include 100% of each property managed by us in North America. Refer to “Annual rental revenue” and “Investment-grade or publicly traded large
cap tenants” under “Definitions and reconciliations” in Item 2 for additional details, including our methodologies of calculating annual rental revenue from unconsolidated real
estate joint ventures and average market capitalization, respectively.
(1) Based on annual rental revenue in effect as of September 30, 2024.
(2) As of June 30, 2024, 2seventy bio, Inc. held $201.9 million of cash, cash equivalents, and marketable securities. In March 2024, Regeneron Pharmaceuticals, Inc., a
publicly traded biotechnology company with investment-grade credit ratings of Baa1 and BBB+ assigned by Moody’s and S&P, respectively, entered into a sublease for
approximately 195,000 RSF, or 62.8% of our annual rental revenue generated from 2seventy bio as of September 30, 2024. Additionally, 90.2% of the annual rental
revenue generated by 2seventy bio is guaranteed by another related public biotechnology company.
(3) Consists of one lease at a property acquired in 2022 with future development and redevelopment opportunities. This lease with Cloud Software Group, Inc. (formerly known
as TIBCO Software, Inc.) was in place when we acquired the property.
(4) Includes (i) ground leases for land at 1455 and 1515 Third Street (two buildings aggregating 422,980 RSF) and (ii) leases at 1655 and 1725 Third Street (two buildings
aggregating 586,208 RSF) in our Mission Bay submarket owned by our unconsolidated real estate joint venture in which we have an ownership interest of 10%. Annual
rental revenue is presented using 100% of the annual rental revenue from our consolidated properties and our share of annual rental revenue from our unconsolidated real
estate joint ventures. Excluding these ground leases, the weighted-average remaining lease term for our top 20 tenants was 7.8 years as of September 30, 2024.
57
Locations of properties
The locations of our properties are diversified among a number of Class A/A+ assets strategically clustered in mega campuses
in AAA life science innovation cluster markets. The following table sets forth the total RSF, number of properties, and annual rental
revenue in effect as of September 30, 2024 in each of our markets in North America (dollars in thousands, except per RSF amounts):
| Market | RSF Operating | Development | Redevelopment | Total | % of Total | Number of Properties Total | Annual Rental Revenue % of Total | Per RSF | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Greater Boston | 10,352,695 | 764,036 | 1,762,974 | (1) | 12,879,705 | 28% | 72 | $833,562 | 38% | $85.09 |
| San Francisco Bay Area | 7,784,590 | 498,142 | 259,689 | 8,542,421 | 18 | 65 | 432,102 | 20 | 63.54 | |
| San Diego | 7,673,315 | 1,186,104 | — | 8,859,419 | 19 | 87 | 330,596 | 15 | 44.90 | |
| Seattle | 3,108,593 | 227,577 | 34,306 | 3,370,476 | 7 | 45 | 137,044 | 6 | 47.78 | |
| Maryland | 3,819,512 | 29,890 | — | 3,849,402 | 8 | 50 | 145,847 | 7 | 40.12 | |
| Research Triangle | 3,770,927 | — | — | 3,770,927 | 8 | 38 | 116,318 | 5 | 31.64 | |
| New York City | 921,686 | — | — | 921,686 | 2 | 4 | 72,439 | 3 | 92.37 | |
| Texas | 1,845,159 | — | 73,298 | 1,918,457 | 4 | 15 | 54,958 | 3 | 31.19 | |
| Canada | 887,737 | — | 139,311 | 1,027,048 | 2 | 11 | 19,790 | 1 | 23.33 | |
| Non-cluster/other markets | 347,806 | — | — | 347,806 | 1 | 10 | 14,623 | 1 | 57.76 | |
| Properties held for sale | 1,261,387 | — | — | 1,261,387 | 3 | 9 | 26,796 | 1 | N/A | |
| North America | 41,773,407 | 2,705,749 | 2,269,578 | 46,748,734 | 100% | 406 | $2,184,075 | 100% | $57.09 | |
| 4,975,327 |
(1) Primarily includes our active redevelopment projects aggregating 735,744 RSF at 40, 50, and 60 Sylvan Road and 840 Winter Street located on the Alexandria Center®
for Life Science – Waltham mega campus. This mega campus project is expected to capture demand in our Route 128 submarket.
Summary of occupancy percentages in North America
The following table sets forth the occupancy percentages for our operating properties and our operating and redevelopment
properties in each of our North America markets, excluding properties held for sale, as of the following dates:
| Market | Operating Properties 9/30/24 | 6/30/24 | 9/30/23 | Operating and Redevelopment Properties 9/30/24 | 6/30/24 | 9/30/23 | |
|---|---|---|---|---|---|---|---|
| Greater Boston | 94.6% | 94.2% | 93.2% | 80.9% | 81.7% | 83.3% | |
| San Francisco Bay Area | 94.1 | 94.0 | 95.3 | 91.1 | 90.7 | 91.9 | |
| San Diego | 96.0 | 95.1 | 90.9 | 96.0 | 95.1 | 90.9 | |
| Seattle | 92.3 | (1) | 94.7 | 95.1 | 91.3 | 93.7 | 90.3 |
| Maryland | 96.2 | 96.5 | 96.6 | 96.2 | 96.5 | 96.6 | |
| Research Triangle | 97.5 | 97.4 | 96.9 | 97.5 | 97.4 | 96.9 | |
| New York City | 85.1 | (2) | 85.1 | 89.4 | 85.1 | 85.1 | 89.4 |
| Texas | 95.5 | 95.5 | 95.1 | 91.8 | 91.8 | 91.5 | |
| Subtotal | 94.9 | 94.7 | 93.9 | 90.0 | 90.2 | 89.9 | |
| Canada | 95.5 | 94.9 | 88.9 | 82.6 | 82.5 | 75.7 | |
| Non-cluster/other markets | 72.8 | 75.6 | 80.5 | 72.8 | 75.6 | 80.5 | |
| North America | 94.7% | 94.6% | 93.7% | 89.7% | 89.9% | 89.4% |
(1) Decline in occupancy relates to the expiration of an acquired non-laboratory lease aggregating 87,273 RSF at one property in our Bothell submarket that is expected to
be converted to laboratory space subject to market conditions and leasing.
(2) The Alexandria Center® for Life Science – New York City mega campus is 95.3% occupied as of September 30, 2024. Occupancy percentage in our New York City
market reflects vacancy at the Alexandria Center® for Life Science – Long Island City property, which was 42.8% occupied as of September 30, 2024.
58
Investments in real estate
A key component of our business model is our disciplined allocation of capital to the development and redevelopment of new
Class A/A+ properties, and property enhancements identified during the underwriting of certain acquired properties, located in
collaborative mega campuses in AAA life science innovation clusters. These projects are focused on providing high-quality, generic, and
reusable spaces that meet the real estate requirements of a wide range of tenants. Upon completion, each development and
redevelopment project is expected to generate increases in rental income, net operating income, and cash flows. Our development and
redevelopment projects are generally in locations that are highly desirable to high-quality entities, which we believe results in higher
occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value. Our pre-construction
activities are undertaken in order to prepare the property for its intended use and include entitlements, permitting, design, site work, and
other activities preceding commencement of construction of aboveground building improvements.
Our investments in real estate consisted of the following as of September 30, 2024 (dollars in thousands):
| Square footage | Operating | Development and Redevelopment Active and Near-Term Construction Under Construction 55% Leased/ Negotiating | Committed Near Term 51% Leased/ Negotiating(1) | Future Opportunities Subject to Market Conditions and Leasing Priority Anticipated | Future | Subtotal | Total | |
|---|---|---|---|---|---|---|---|---|
| Operating | 40,512,020 | — | — | — | — | — | 40,512,020 | |
| New Class A/A+ development and redevelopment properties | — | 4,975,327 | 492,570 | 2,163,784 | 27,582,766 | 35,214,447 | 35,214,447 | |
| Future development and redevelopment square feet currently included in rental properties(2) | — | — | (159,884) | (258,596) | (2,957,559) | (3,376,039) | (3,376,039) | |
| Total square footage, excluding properties held for sale | 40,512,020 | 4,975,327 | 332,686 | 1,905,188 | 24,625,207 | 31,838,408 | 72,350,428 | |
| Properties held for sale | 1,261,387 | — | — | — | — | — | 1,261,387 | |
| Total square footage | 41,773,407 | 4,975,327 | 332,686 | 1,905,188 | 24,625,207 | 31,838,408 | 73,611,815 | (3) |
| Investments in real estate | ||||||||
| Gross book value as of September 30, 2024(4) | $29,235,994 | $4,335,573 | $69,521 | $578,694 | $4,356,637 | $9,340,425 | $38,576,419 |
(1) Represents one committed near-term project expected to commence construction during the next two years after September 30, 2024.
(2) Refer to “Investments in real estate” under “Definitions and reconciliations” in Item 2 for additional details, including future development and redevelopment square feet
currently included in rental properties.
(3) We expect to continue pursuing our strategy to fund a significant portion of our capital requirements for the year ending December 31, 2024 with dispositions primarily
focused on sales of properties and land parcels not integral to our mega campus strategy.
(4) Balances exclude accumulated depreciation and our share of the cost basis associated with our properties held by our unconsolidated real estate joint ventures, which is
classified as investments in unconsolidated real estate joint ventures in our consolidated balance sheets.
59
Acquisitions
Our real estate asset acquisitions during the nine months ended September 30, 2024 and pending as of the date of this report consisted of the following (dollars in thousands):
| Property Completed during the nine months ended September 30, 2024: | Submarket/Market | Date of Purchase Future Development(1) | Number of Properties Operating With Future Development/ Redevelopment(1) | Operating Occupancy Purchase Price | Square Footage |
|---|---|---|---|---|---|
| 285, 299, 307, and 345 Dorchester Avenue (60% interest in consolidated JV)(2) | Seaport Innovation District/ Greater Boston | 1/30/24 | — | N/A | 1,040,000 — $155,321 |
| Other | 46,490 | ||||
| 201,811 | |||||
| Completed in October 2024: | |||||
| 428 Westlake Avenue North | Lake Union/Seattle | 10/1/24 | 1 | 100% | — 88,514 47,600 |
| $249,411 | |||||
| 2024 guidance range for acquisitions | $250,000 – $750,000 |
(1) We expect to provide total estimated costs and related yields for development and significant redevelopment projects in the future, subsequent to the commencement of construction.
(2) Refer to Note 4 – “Consolidated and unconsolidated real estate joint ventures” to our unaudited consolidated financial statements in Item 1 for additional details.
60
Dispositions
Our completed dispositions of real estate assets during the nine months ended September 30, 2024 and pending as of the date of this report consisted of the following (dollars in
thousands):
| Property Submarket/Market Completed during the six months ended June 30, 2024: Dispositions of 100% interest in properties not integral to our mega campus strategy | Date of Sale | Interest Sold | RSF Capitalization Rate Capitalization Rate (Cash Basis) Sales Price | Sales Price per RSF | |
|---|---|---|---|---|---|
| 99 A Street(1) Seaport Innovation District/ Greater Boston | 3/8/24 | 100% | 235,000 N/A N/A $13,350 | N/A | |
| Other | 3,863 | ||||
| 17,213 | |||||
| Completed during the three months ended September 30, 2024: | |||||
| Sale to longstanding tenant | |||||
| 1165 Eastlake Avenue East Lake Union/Seattle | 9/12/24 | 100% | 100,086 4.7% 4.9% 149,985 | (2) | $1,499 |
| Dispositions of properties not integral to our mega campus strategy | |||||
| 219 East 42nd Street New York City/New York City | 7/9/24 | 100% | 349,947 N/A N/A 60,000 | (3) | N/A |
| Other | 11,511 | ||||
| 221,496 | (4) | ||||
| Dispositions completed during the nine months ended September 30, 2024 | 238,709 | ||||
| Completed in October 2024: | |||||
| Dispositions of properties not integral to our mega campus strategy | |||||
| 14225 Newbrook Drive Northern Virginia/Maryland | 10/15/24 | 100% | 248,186 7.6% 7.4% 80,500 | (5) | $324 |
| 319,209 | |||||
| Pending dispositions for the fourth quarter of 2024 subsequent to the date of this report: | |||||
| Subject to non-refundable deposits | |||||
| Sale to longstanding tenant Greater Boston | 4Q24 | 100% | 8.5% 6.3% 369,439 | (6) | |
| Other | 207,713 | ||||
| 577,152 | |||||
| Subject to executed letters of intent and/or purchase and sale agreements | 602,500 | (6) | |||
| 1,179,652 | (7) | ||||
| $1,498,861 | |||||
| 2024 guidance range for dispositions and common equity | $1,050,000 – $2,050,000 |
(1) We completed the sale during the three months ended March 31, 2024 and recognized no gain or loss. Refer to Note 3 – “Investments in real estate” to our unaudited consolidated financial statements in Item 1 for additional information.
(2) Upon completion of the sale, we recognized a gain on sale of real estate aggregating $21.5 million during the three months ended September 30, 2024.
(3) The property was leased to a single tenant with a July 2024 lease expiration and had annual net operating income of $18.6 million based on three months ended June 30, 2024 annualized. This property was previously considered to be a
potential development project upon expiration of the in-place non-laboratory space lease.
(4) Dispositions completed during the three months ended September 30, 2024 had annual net operating income of $26.5 million (based on three months ended June 30, 2024 annualized) with a weighted-average disposition date of July 28,
2024 (weighted by net operating income for the three months ended June 30, 2024 annualized).
(5) Demonstrating the long-term enduring value of our laboratory facilities, Alexandria successfully operated our only asset in the Northern Virginia submarket from its acquisition in 1997 (prior to our IPO) through its sale in October 2024. Upon
completion of the sale, we recognized a gain on sale of real estate aggregating $37.1 million.
(6) Refer to Note 16 – “Subsequent events” to our unaudited consolidated financial statements in Item 1 for additional information.
(7) Pending dispositions subsequent to the date of this report have estimated annual net operating income of approximately $95.8 million (based on three months ended September 30, 2024 annualized) with a weighted-average estimated
disposition date of December 5, 2024 (weighted by net operating income for the three months ended September 30, 2024 annualized). Approximately half of our pending dispositions are non-core stabilized stand-alone properties with
weighted-average capitalization rates of 8.5% and 7.0% (cash basis), and the remaining half are land and non-stabilized properties that have vacancy or significant near-term lease expirations that will require capital to re-tenant, including
one building with approximately 72% of non-laboratory space.
61
New Class A/A+ development and redevelopment properties
ALEXANDRIA’S FUTURE GROWTH IN
ANNUAL NET OPERATING INCOME FROM
DEVELOPMENT AND REDEVELOPMENT DELIVERIES
$510 MILLION
(1)
Placed Into Service
Expected to Be Placed Into Service
(2)
| YTD 3Q24 | 3Q24 |
| $63M | $21M |
| 945,118 RSF | 316,691 RSF |
| 100% Leased |
(3)
| 4Q24–4Q25 | 1Q26–1Q28 |
| $158M | $352M |
| Aggregating 5.5M RSF | |
| 55% Leased/Negotiating |
Refer to “Net operating income” under “Definitions and reconciliations” in Item 2 for additional details, including its reconciliation from the most directly comparable financial measures presented in accordance with GAAP.
(1) Our share of incremental annual net operating income from development and redevelopment projects expected to be placed into service primarily commencing from 4Q24 through 1Q28 is projected to be $407 million.
(2) Represents expected incremental annual net operating income to be placed into service from deliveries of projects undergoing construction and one committed near-term project expected to commence construction in the next two
years.
(3) Includes (i) 1.0 million RSF that is expected to stabilize through 2025 and is 92% leased/negotiating and (ii) expected partial deliveries through 4Q25 from projects expected to stabilize in 2026 and beyond. Refer to the initial and stabilized
occupancy years under “New Class A/A+ development and redevelopment properties: current projects” in Item 2 for additional details.
62
New Class A/A+ development and redevelopment properties: recent deliveries
| 500 North Beacon Street and 4 Kingsbury Avenue(1) | 651 Gateway Boulevard | 1150 Eastlake Avenue East |
|---|---|---|
| Greater Boston/ Cambridge/Inner Suburbs | San Francisco Bay Area/ South San Francisco | Seattle/Lake Union |
| 138,537 RSF | 67,017 RSF | 311,631 RSF |
| 100% Occupancy | 100% Occupancy | 100% Occupancy |
| 9810 Darnestown Road | 9820 Darnestown Road | 9808 Medical Center Drive |
|---|---|---|
| Maryland/Rockville | Maryland/Rockville | Maryland/Rockville |
| 195,435 RSF | 250,000 RSF | 65,171 RSF |
| 100% Occupancy | 100% Occupancy | 100% Occupancy |
(1) Image represents 500 North Beacon Street on The Arsenal on the Charles mega campus.
63
New Class A/A+ development and redevelopment properties: recent deliveries (continued)
The following table presents development and redevelopment of new Class A/A+ projects placed into service during the nine months ended September 30, 2024 (dollars in
thousands):
Incremental Annual Net Operating Income Generated From YTD 3Q24 Deliveries
Aggregated $63 Million, Including $21 Million in 3Q24
| Property/Market/Submarket Development projects | 3Q24 Delivery Date(1) Prior to 1/1/24 | Our Ownership Interest 1Q24 | RSF Placed in Service 2Q24 | 3Q24 RSF | Total Investment | Occupancy Percentage(2) Initial Stabilized | Total Project Initial Stabilized (Cash Basis) | Unlevered Yields | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 99 Coolidge Avenue/Greater Boston/Cambridge/ Inner Suburbs | N/A | 75.0% | 43,568 | 72,846 | — | — | 116,414 | 100% | 320,809 | $468,000 | 7.1% | 7.0% |
| 500 North Beacon Street and 4 Kingsbury Avenue/ Greater Boston/Cambridge/Inner Suburbs | N/A | 100% | — | 100,624 | 37,913 | — | 138,537 | 100% | 248,018 | 427,000 | 6.2 | 5.5 |
| 1150 Eastlake Avenue East/Seattle/Lake Union | 7/16/24 | 100% | 278,282 | — | 2,079 | 31,270 | 311,631 | 100% | 311,631 | 442,000 | 6.6 | 6.7 |
| 9810 Darnestown Road/Maryland/Rockville | N/A | 100% | — | — | 195,435 | — | 195,435 | 100% | 195,435 | 135,000 | 7.1 | 6.2 |
| 9820 Darnestown Road/Maryland/Rockville | 8/21/24 | 100% | — | — | — | 250,000 | 250,000 | 100% | 250,000 | 177,000 | 8.7 | 5.6 |
| 9808 Medical Center Drive/Maryland/Rockville | 7/25/24 | 100% | 26,460 | — | 25,655 | 13,056 | 65,171 | 100% | 95,061 | 115,000 | 5.4 | 5.4 |
| Redevelopment projects | ||||||||||||
| 651 Gateway Boulevard/San Francisco Bay Area/ South San Francisco | 7/12/24 | 50.0% | — | 44,652 | — | 22,365 | 67,017 | 100% | 326,706 | 487,000 | 5.0 | 5.1 |
| Alexandria Center® for Advanced Technologies – Monte Villa Parkway/Seattle/Bothell | N/A | 100% | 65,086 | 115,598 | — | — | 180,684 | 100% | 460,934 | 229,000 | 6.3 | 6.2 |
| Canada | N/A | 100% | 44,862 | 9,725 | 23,900 | — | 78,487 | 100% | 250,790 | 113,000 | 6.4 | 6.3 |
| Weighted average/total | 8/11/24 | 458,258 | 343,445 | 284,982 | 316,691 | 1,403,376 | 2,459,384 | $2,593,000 | 6.4% | 6.0% |
(1) Represents the average delivery date for deliveries that occurred during the three months ended September 30, 2024, weighted by annual rental revenue.
(2) Occupancy relates to total operating RSF placed in service as of the most recent delivery.
64
New Class A/A+ development and redevelopment properties: current projects
| 99 Coolidge Avenue | 500 North Beacon Street and 4 Kingsbury Avenue(1) | 311 Arsenal Street | 201 Brookline Avenue | 401 Park Drive |
|---|---|---|---|---|
| Greater Boston/ Cambridge/Inner Suburbs | Greater Boston/ Cambridge/Inner Suburbs | Greater Boston/ Cambridge/Inner Suburbs | Greater Boston/Fenway | Greater Boston/Fenway |
| 204,395 RSF | 109,481 RSF | 308,446 RSF | 58,149 RSF | 159,959 RSF |
| 40% Leased/Negotiating | 92% Leased | 21% Leased | 100% Leased | 14% Leased |
| 421 Park Drive | 40, 50, and 60 Sylvan Road(2) | 840 Winter Street | 1450 Owens Street(3) | 651 Gateway Boulevard |
|---|---|---|---|---|
| Greater Boston/Fenway | Greater Boston/Route 128 | Greater Boston/Route 128 | San Francisco Bay Area/ Mission Bay | San Francisco Bay Area/ South San Francisco |
| 392,011 RSF | 596,064 RSF | 139,680 RSF | 212,796 RSF | 259,689 RSF |
| 13% Leased | 31% Leased | 100% Leased | —% Leased/Negotiating | 25% Leased/Negotiating |
(1) Image represents 500 North Beacon Street on The Arsenal on the Charles mega campus.
(2) Image represents 60 Sylvan Road on the Alexandria Center® for Life Science – Waltham mega campus. The project is expected to capture demand in our Route 128 submarket.
(3) Image represents a multi-tenant project expanding our existing Alexandria Center® for Science and Technology – Mission Bay mega campus, where our joint venture partner will fund 100% of the construction cost until it attains an
ownership interest of 75%, after which it will contribute its respective share of additional capital. We are in negotiations with a biomedical institution for the sale of a 50% condominium interest in this property.
65
New Class A/A+ development and redevelopment properties: current projects (continued)
| 230 Harriet Tubman Way | 10935, 10945, and 10955 Alexandria Way(1) | 4135 Campus Point Court | 4155 Campus Point Court |
|---|---|---|---|
| San Francisco Bay Area/ South San Francisco | San Diego/Torrey Pines | San Diego/ University Town Center | San Diego/ University Town Center |
| 285,346 RSF | 334,996 RSF | 426,927 RSF | 171,102 RSF |
| 100% Leased | 100% Leased | 100% Leased | 100% Leased |
| 10075 Barnes Canyon Road | 701 Dexter Avenue North(2) | Alexandria Center® for Advanced Technologies – Monte Villa Parkway(3) | 9808 Medical Center Drive | 8800 Technology Forest Place |
|---|---|---|---|---|
| San Diego/Sorrento Mesa | Seattle/Lake Union | Seattle/Bothell | Maryland/Rockville | Texas/Greater Houston |
| 253,079 RSF | 227,577 RSF | 34,306 RSF | 29,890 RSF | 73,298 RSF |
| 70% Leased | —% Leased/Negotiating | 98% Leased | 76% Leased/Negotiating | 41% Leased |
(1) Image represents 10955 Alexandria Way on the One Alexandria Square mega campus.
(2) We initially started this project due to strong demand from neighboring tenants but strategically paused in the first quarter of 2023. We have resumed construction activities at this project in order to maintain our existing entitlements and
permits. We have interest from various prospective tenants, including from multinational pharmaceutical companies. Beyond this purpose-built life science asset, there is no competitive supply expected to be delivered in 2025 or 2026 in
our Lake Union submarket. As of September 30, 2024, we are 95.3% occupied in our Lake Union submarket.
(3) Image represents 3755 Monte Villa Parkway.
66
New Class A/A+ development and redevelopment properties: current projects (continued)
The following tables set forth a summary of our new Class A/A+ development and redevelopment properties under construction and pre-leased/negotiating near-term projects as of
September 30, 2024 (dollars in thousands):
| Property/Market/Submarket Dev/Redev Under construction 2024 and 2025 stabilization | In Service | Square Footage | CIP | Total | Percentage Leased | Leased/ Negotiating | Occupancy(1) Initial | Stabilized | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 500 North Beacon Street and 4 Kingsbury Avenue/Greater Boston/ Cambridge/Inner Suburbs | Dev | 138,537 | 109,481 | 248,018 | 92% | 92% | 1Q24 | 2025 | ||
| 201 Brookline Avenue/Greater Boston/Fenway | Dev | 451,967 | 58,149 | 510,116 | 100 | 100 | 3Q22 | 4Q24 | ||
| 840 Winter Street/Greater Boston/Route 128 | Redev | 28,534 | 139,680 | 168,214 | 100 | 100 | 4Q24 | 2025 | ||
| 230 Harriet Tubman Way/San Francisco Bay Area/South San Francisco | Dev | — | 285,346 | 285,346 | 100 | 100 | 1Q25 | 1Q25 | ||
| 4155 Campus Point Court/San Diego/University Town Center | Dev | — | 171,102 | 171,102 | 100 | 100 | 4Q24 | 4Q24 | ||
| Alexandria Center® for Advanced Technologies – Monte Villa Parkway/Seattle/Bothell | Redev | 426,628 | 34,306 | 460,934 | 98 | 98 | 1Q23 | 4Q24 | ||
| 9808 Medical Center Drive/Maryland/Rockville | Dev | 65,171 | 29,890 | 95,061 | 69 | 76 | 3Q23 | 4Q24 | ||
| 8800 Technology Forest Place/Texas/Greater Houston | Redev | 50,094 | 73,298 | 123,392 | 41 | 41 | 2Q23 | 2025 | ||
| Canada | Redev | 111,479 | 139,311 | 250,790 | 73 | 73 | 3Q23 | 2025 | ||
| 1,272,410 | 1,040,563 | 2,312,973 | 91 | 92 | ||||||
| 2026 and beyond stabilization | ||||||||||
| One Hampshire Street/Greater Boston/Cambridge | Redev | — | 104,956 | 104,956 | — | — | 2027 | 2028 | ||
| 311 Arsenal Street/Greater Boston/Cambridge/Inner Suburbs | Redev | 82,216 | (2) | 308,446 | 390,662 | 21 | 21 | 2027 | 2027 | |
| 99 Coolidge Avenue/Greater Boston/Cambridge/Inner Suburbs | Dev | 116,414 | 204,395 | 320,809 | 40 | 40 | 4Q23 | 2026 | ||
| 401 Park Drive/Greater Boston/Fenway | Redev | — | 159,959 | 159,959 | 14 | 14 | 2024 | 2026 | ||
| 421 Park Drive/Greater Boston/Fenway | Dev | — | 392,011 | 392,011 | 13 | 13 | 2026 | 2027 | ||
| 40, 50, and 60 Sylvan Road/Greater Boston/Route 128 | Redev | — | 596,064 | 596,064 | 31 | 31 | 2025 | 2027 | ||
| Other/Greater Boston | Redev | — | 453,869 | 453,869 | — | — | (3) | 2027 | 2027 | |
| 1450 Owens Street/San Francisco Bay Area/Mission Bay | Dev | — | 212,796 | 212,796 | — | — | (4) | 2025 | 2026 | |
| 651 Gateway Boulevard/San Francisco Bay Area/South San Francisco | Redev | 67,017 | 259,689 | 326,706 | 21 | 25 | 1Q24 | 2026 | ||
| 10935, 10945, and 10955 Alexandria Way/San Diego/Torrey Pines | Dev | — | 334,996 | 334,996 | 100 | 100 | 4Q24 | 2026 | ||
| 4135 Campus Point Court/San Diego/University Town Center | Dev | — | 426,927 | 426,927 | 100 | 100 | 2026 | 2026 | ||
| 10075 Barnes Canyon Road/San Diego/Sorrento Mesa | Dev | — | 253,079 | 253,079 | 70 | 70 | 2025 | 2026 | ||
| 701 Dexter Avenue North/Seattle/Lake Union | Dev | — | 227,577 | 227,577 | — | — | (5) | 2026 | 2027 | |
| 265,647 | 3,934,764 | 4,200,411 | 35 | 36 | ||||||
| 1,538,057 | 4,975,327 | 6,513,384 | 55 | 55 | ||||||
| Committed near-term project expected to commence construction in the next two years | ||||||||||
| 4165 Campus Point Court/San Diego/University Town Center | Dev | — | 492,570 | 492,570 | — | 51 | ||||
| Total | 1,538,057 | 5,467,897 | 7,005,954 | 51% | 55% | |||||
| (1)Initial occupancy dates are subject to leasing and/or market conditions. Stabilized occupancy may vary depending on single tenancy versus multi-tenancy. Multi-tenant projects may increase in occupancy over a period of time. (2)We expect to redevelop an additional 25,312 RSF of space occupied as of September 30, 2024 into laboratory space upon expiration of the existing leases through the second half of 2025. Refer to “Investments in real estate” under “Definitions and reconciliations” in Item 2 for additional information. (3)Represents a project focused on demand from our existing tenants in our adjacent properties/campuses that will address demand from other non-Alexandria properties/campuses. (4)Represents a multi-tenant project expanding our existing mega campus, where our joint venture partner will fund 100% of the construction cost until it attains an ownership interest of 75%, after which it will contribute its respective share of additional capital. We are in negotiations with a biomedical institution for the sale of a 50% condominium interest in this property. (5)We initially started this project due to strong demand from neighboring tenants but strategically paused in the first quarter of 2023. We have resumed construction activities at this project in order to maintain our existing entitlements and permits. We have interest from various prospective tenants, including from multinational pharmaceutical companies. Beyond this purpose-built life science asset, there is no competitive supply expected to be delivered in 2025 or 2026 in our Lake Union submarket. As of September 30, 2024, we are 95.3% occupied in our Lake Union submarket. |
67
New Class A/A+ development and redevelopment properties: current projects (continued)
| Property/Market/Submarket Under construction 2024 and 2025 stabilization | Our Ownership Interest In Service | At 100% CIP | Cost to Complete | Unlevered Yields Total at Completion Initial Stabilized Initial Stabilized (Cash Basis) |
|---|---|---|---|---|
| 500 North Beacon Street and 4 Kingsbury Avenue/Greater Boston/ Cambridge/Inner Suburbs | 100% | $284,645 | $115,506 | $26,849 $427,000 6.2% 5.5% |
| 201 Brookline Avenue/Greater Boston/Fenway | 99.0% | 665,877 | 91,610 | 17,513 775,000 7.2% 6.5% |
| 840 Winter Street/Greater Boston/Route 128 | 100% | 13,653 | 187,366 | 35,981 237,000 7.6% 6.5% |
| 230 Harriet Tubman Way/San Francisco Bay Area/South San Francisco | 47.9% | — | 350,231 | 159,769 510,000 7.4% 6.4% |
| 4155 Campus Point Court/San Diego/University Town Center | 55.0% | — | 140,300 | 43,700 184,000 8.0% 6.4% |
| Alexandria Center® for Advanced Technologies – Monte Villa Parkway/Seattle/Bothell | 100% | 193,823 | 11,977 | 23,200 229,000 6.3% 6.2% |
| 9808 Medical Center Drive/Maryland/Rockville | 100% | 79,320 | 33,018 | 2,662 115,000 5.4% 5.4% |
| 8800 Technology Forest Place/Texas/Greater Houston | 100% | 57,315 | 46,202 | 8,483 112,000 6.3% 6.0% |
| Canada | 100% | 50,219 | 50,044 | 12,737 113,000 6.4% 6.3% |
| 1,344,852 | 1,026,254 | |||
| 2026 and beyond stabilization(1) | ||||
| One Hampshire Street/Greater Boston/Cambridge | 100% | — | 161,328 | TBD |
| 311 Arsenal Street/Greater Boston/Cambridge/Inner Suburbs | 100% | 60,625 | 233,563 | |
| 99 Coolidge Avenue/Greater Boston/Cambridge/Inner Suburbs | 75.0% | 136,527 | 192,432 | 139,041 468,000 7.1% 7.0% |
| 401 Park Drive/Greater Boston/Fenway | 100% | — | 194,421 | TBD |
| 421 Park Drive/Greater Boston/Fenway | 99.7% | — | 422,278 | |
| 40, 50, and 60 Sylvan Road/Greater Boston/Route 128 | 100% | — | 437,356 | |
| Other/Greater Boston | 100% | — | 148,804 | |
| 1450 Owens Street/San Francisco Bay Area/Mission Bay | 25.4% | — | 234,665 | |
| 651 Gateway Boulevard/San Francisco Bay Area/South San Francisco | 50.0% | 87,357 | 256,413 | 143,230 487,000 5.0% 5.1% |
| 10935, 10945, and 10955 Alexandria Way/San Diego/Torrey Pines | 100% | — | 359,926 | 143,074 503,000 6.2% 5.8% |
| 4135 Campus Point Court/San Diego/University Town Center | 55.0% | — | 292,913 | 231,087 524,000 6.6% 6.2% |
| 10075 Barnes Canyon Road/San Diego/Sorrento Mesa | 50.0% | — | 168,582 | 152,418 321,000 5.5% 5.7% |
| 701 Dexter Avenue North/Seattle/Lake Union | 100% | — | 206,638 | TBD |
| 284,509 | 3,309,319 | |||
| 1,629,361 | 4,335,573 | |||
| Committed near-term project expected to commence construction in the next two years | ||||
| 4165 Campus Point Court/San Diego/University Town Center | 55.0% | — | 69,521 | TBD |
| Total | $1,629,361 | $4,405,094 | $3,780,000 (2) $9,820,000 (2) | |
| Our share of investment(2)(3) | $1,550,000 | $3,570,000 | $3,030,000 $8,150,000 | |
| Refer to “Initial stabilized yield (unlevered)” under “Definitions and reconciliations” in Item 2 for additional information. (1)We expect to provide total estimated costs and related yields for each project with estimated stabilization in 2026 and beyond over the next several quarters. (2)Represents dollar amount rounded to the nearest $10 million and includes preliminary estimated amounts for projects listed as TBD. (3)Represents our share of investment based on our ownership percentage upon completion of development or redevelopment projects. |
68
New Class A/A+ development and redevelopment properties: summary of pipeline
69% of Our Total Development and Redevelopment Pipeline RSF Is Within Our Mega Campuses
The following table summarizes the key information for all our development and redevelopment projects in North America as of September 30, 2024 (dollars in thousands):
| Market Property/Submarket Greater Boston | Our Ownership Interest Under Construction | Book Value Development and Redevelopment Active and Near-Term Construction Committed Near Term | Square Footage Future Opportunities Subject to Market Conditions and Leasing Priority Anticipated | Future | Total(1) | ||
|---|---|---|---|---|---|---|---|
| Mega Campus: Alexandria Center® at One Kendall Square/ Cambridge | 100% | $161,328 | 104,956 | — | — | — | 104,956 |
| One Hampshire Street | |||||||
| Mega Campus: The Arsenal on the Charles/Cambridge/Inner Suburbs | 100% | 360,538 | 417,927 | — | 25,312 | 34,157 | 477,396 |
| 311 Arsenal Street, 500 North Beacon Street, and 4 Kingsbury Avenue | |||||||
| Mega Campus: 480 Arsenal Way and 446, 458, 500, and 550 Arsenal Street, and 99 Coolidge Avenue/Cambridge/Inner Suburbs | (2) | 279,763 | 204,395 | — | — | 902,000 | 1,106,395 |
| 446, 458, 500, and 550 Arsenal Street, and 99 Coolidge Avenue | |||||||
| Mega Campus: Alexandria Center® for Life Science – Fenway/ Fenway | (3) | 708,309 | 610,119 | — | — | — | 610,119 |
| 201 Brookline Avenue and 401 and 421 Park Drive | |||||||
| Mega Campus: Alexandria Center® for Life Science – Waltham/ Route 128 | 100% | 687,346 | 735,744 | — | — | 515,000 | 1,250,744 |
| 40, 50, and 60 Sylvan Road, 35 Gatehouse Drive, and 840 Winter Street | |||||||
| Mega Campus: Alexandria Center® at Kendall Square/ Cambridge | 100% | 126,688 | — | — | — | 216,455 | 216,455 |
| 100 Edwin H. Land Boulevard | |||||||
| Mega Campus: Alexandria Technology Square®/Cambridge | 100% | 7,881 | — | — | — | 100,000 | 100,000 |
| Mega Campus: 285, 299, 307, and 345 Dorchester Avenue/ Seaport Innovation District | 60.0% | 286,300 | — | — | — | 1,040,000 | 1,040,000 |
| 10 Necco Street/Seaport Innovation District | 100% | 105,111 | — | — | — | 175,000 | 175,000 |
| Mega Campus: One Moderna Way/Route 128 | 100% | 26,052 | — | — | — | 1,085,000 | 1,085,000 |
| 215 Presidential Way/Route 128 | 100% | 6,816 | — | — | — | 112,000 | 112,000 |
| Other development and redevelopment projects | (4) | 310,381 | 453,869 | — | — | 1,323,541 | 1,777,410 |
| $3,066,513 | 2,527,010 | — | 25,312 | 5,503,153 | 8,055,475 | ||
| Refer to “Mega campus” under “Definitions and reconciliations” in Item 2 for additional information. (1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to “Investments in real estate” under “Definitions and reconciliations” in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties. (2)We have a 75.0% interest in 99 Coolidge Avenue aggregating 204,395 RSF and 100.0% interest in 446, 458, 500, and 550 Arsenal Street aggregating 902,000 RSF. (3)We have a 99.0% interest in 201 Brookline Avenue aggregating 58,149 RSF, a 100% interest in 401 Park Drive aggregating 159,959 RSF, and a 99.7% interest in 421 Park Drive aggregating 392,011 RSF. (4)Includes a property in which we own a partial interest through a real estate joint venture. |
69
New Class A/A+ development and redevelopment properties: summary of pipeline (continued)
| Market Property/Submarket San Francisco Bay Area | Our Ownership Interest Under Construction | Book Value Development and Redevelopment Active and Near-Term Construction Committed Near Term | Square Footage Future Opportunities Subject to Market Conditions and Leasing Priority Anticipated | Future | Total(1) | ||
|---|---|---|---|---|---|---|---|
| Mega Campus: Alexandria Center® for Science and Technology – Mission Bay/Mission Bay | 25.4% | $234,665 | 212,796 | — | — | — | 212,796 |
| 1450 Owens Street | |||||||
| Alexandria Center® for Life Science – Millbrae/South San Francisco | 47.9% | 510,162 | 285,346 | — | 198,188 | 150,213 | 633,747 |
| 230 Harriet Tubman Way, 201 and 231 Adrian Road, and 6 and 30 Rollins Road | |||||||
| Mega Campus: Alexandria Technology Center® – Gateway/ South San Francisco | 50.0% | 283,002 | 259,689 | — | — | 291,000 | 550,689 |
| 651 Gateway Boulevard | |||||||
| Mega Campus: Alexandria Center® for Advanced Technologies – Tanforan/South San Francisco | 100% | 397,159 | — | — | 150,000 | 1,780,000 | 1,930,000 |
| 1122, 1150, and 1178 El Camino Real | |||||||
| Mega Campus: Alexandria Center® for Advanced Technologies – South San Francisco/South San Francisco | 100% | 6,655 | — | — | 107,250 | 90,000 | 197,250 |
| 211(2) and 269 East Grand Avenue | |||||||
| Mega Campus: Alexandria Center® for Life Science – San Carlos/Greater Stanford | 100% | 446,892 | — | — | 105,000 | 1,392,830 | 1,497,830 |
| 960 Industrial Road, 987 and 1075 Commercial Street, and 888 Bransten Road | |||||||
| 3825 and 3875 Fabian Way/Greater Stanford | 100% | 154,174 | — | — | — | 478,000 | 478,000 |
| 2100, 2200, 2300, and 2400 Geng Road/Greater Stanford | 100% | 36,509 | — | — | — | 240,000 | 240,000 |
| 901 California Avenue/Greater Stanford | 100% | 19,770 | — | — | — | 56,924 | 56,924 |
| Mega Campus: 88 Bluxome Street/SoMa | 100% | 392,785 | — | — | — | 1,070,925 | 1,070,925 |
| Other development and redevelopment projects | 100% | — | — | — | — | 25,000 | 25,000 |
| $2,481,773 | 757,831 | — | 560,438 | 5,574,892 | 6,893,161 | ||
| Refer to “Mega campus” under “Definitions and reconciliations” in Item 2 for additional information. (1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to “Investments in real estate” under “Definitions and reconciliations” in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties. (2)We own a partial interest in this property through a real estate joint venture. Refer to Note 4 – “Consolidated and unconsolidated real estate joint ventures” to our unaudited consolidated financial statements in Item 1 for additional details. |
70
New Class A/A+ development and redevelopment properties: summary of pipeline (continued)
| Market Property/Submarket San Diego | Our Ownership Interest Under Construction | Book Value Development and Redevelopment Active and Near-Term Construction Committed Near Term | Square Footage Future Opportunities Subject to Market Conditions and Leasing Priority Anticipated | Future | Total(1) | ||
|---|---|---|---|---|---|---|---|
| Mega Campus: One Alexandria Square/Torrey Pines | 100% | $417,621 | 334,996 | — | — | 125,280 | 460,276 |
| 10935, 10945, and 10955 Alexandria Way and 10975 and 10995 Torreyana Road | |||||||
| Mega Campus: Campus Point by Alexandria/University Town Center | 55.0% | 671,303 | 598,029 | 492,570 | — | 650,000 | 1,740,599 |
| 10010(2), 10140(2), and 10260 Campus Point Drive and 4135, 4155, 4161, 4165, and 4275(2) Campus Point Court | |||||||
| Mega Campus: SD Tech by Alexandria/Sorrento Mesa | 50.0% | 317,172 | 253,079 | — | 250,000 | 243,845 | 746,924 |
| 9805 Scranton Road and 10065 and 10075 Barnes Canyon Road | |||||||
| 11255 and 11355 North Torrey Pines Road/Torrey Pines | 100% | 150,187 | — | — | 153,000 | 62,000 | 215,000 |
| Costa Verde by Alexandria/University Town Center | 100% | 138,107 | — | — | — | 537,000 | 537,000 |
| 8410-8750 Genesee Avenue and 4282 Esplanade Court | |||||||
| Mega Campus: 5200 Illumina Way/University Town Center | 51.0% | 17,441 | — | — | — | 451,832 | 451,832 |
| ARE Towne Centre/University Town Center | 100% | 19,869 | — | — | — | 230,000 | 230,000 |
| 9363, 9373, and 9393 Towne Centre Drive | |||||||
| 9625 Towne Centre Drive/University Town Center | 30.0% | 837 | — | — | — | 100,000 | 100,000 |
| Mega Campus: Sequence District by Alexandria/Sorrento Mesa | 100% | 46,323 | — | — | — | 1,798,915 | 1,798,915 |
| 6260, 6290, 6310, 6340, 6350, and 6450 Sequence Drive | |||||||
| Scripps Science Park by Alexandria/Sorrento Mesa | 100% | 120,941 | — | — | — | 598,349 | 598,349 |
| 10048, 10219, 10256, and 10260 Meanley Drive and 10277 Scripps Ranch Boulevard | |||||||
| Pacific Technology Park/Sorrento Mesa | 50.0% | 23,857 | — | — | — | 149,000 | 149,000 |
| 9444 Waples Street | |||||||
| 4025, 4031, 4045, and 4075 Sorrento Valley Boulevard/Sorrento Valley | 100% | 43,641 | — | — | — | 247,000 | 247,000 |
| Other development and redevelopment projects | (3) | 75,716 | — | — | — | 475,000 | 475,000 |
| $2,043,015 | 1,186,104 | 492,570 | 403,000 | 5,668,221 | 7,749,895 | ||
| Refer to “Mega campus” under “Definitions and reconciliations” in Item 2 for additional information. (1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to “Investments in real estate” under “Definitions and reconciliations” in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties. (2)We have a 100% interest in this property. (3)Includes a property in which we own a partial interest through a real estate joint venture. |
71
New Class A/A+ development and redevelopment properties: summary of pipeline (continued)
| Market Property/Submarket Seattle | Our Ownership Interest Under Construction | Book Value Development and Redevelopment Active and Near-Term Construction Committed Near Term | Square Footage Future Opportunities Subject to Market Conditions and Leasing Priority Anticipated | Future | Total(1) | ||
|---|---|---|---|---|---|---|---|
| Mega Campus: Alexandria Center® for Life Science – South Lake Union/Lake Union | (2) | $485,628 | 227,577 | — | 869,000 | 188,400 | 1,284,977 |
| 601 and 701 Dexter Avenue North and 800 Mercer Street | |||||||
| Alexandria Center® for Advanced Technologies – Monte Villa Parkway/Bothell | 100% | 11,977 | 34,306 | — | — | — | 34,306 |
| 3301 Monte Villa Parkway | |||||||
| 830 and 1010 4th Avenue South/SoDo | 100% | 59,262 | — | — | — | 597,313 | 597,313 |
| 410 West Harrison Street/Elliott Bay | 100% | — | — | — | — | 91,000 | 91,000 |
| Mega Campus: Alexandria Center® for Advanced Technologies – Canyon Park/Bothell | 100% | 17,439 | — | — | — | 230,000 | 230,000 |
| 21660 20th Avenue Southeast | |||||||
| Other development and redevelopment projects | 100% | 142,484 | — | — | — | 706,087 | 706,087 |
| 716,790 | 261,883 | — | 869,000 | 1,812,800 | 2,943,683 | ||
| Maryland | |||||||
| Mega Campus: Alexandria Center® for Life Science – Shady Grove/Rockville | 100% | 54,904 | 29,890 | — | — | 296,000 | 325,890 |
| 9808 Medical Center Drive and 9830 Darnestown Road | |||||||
| 54,904 | 29,890 | — | — | 296,000 | 325,890 | ||
| Research Triangle | |||||||
| Mega Campus: Alexandria Center® for Advanced Technologies and Agtech – Research Triangle/Research Triangle | 100% | 103,653 | — | — | 180,000 | 990,000 | 1,170,000 |
| 4 and 12 Davis Drive | |||||||
| Mega Campus: Alexandria Center® for Life Science – Durham/ Research Triangle | 100% | 176,524 | — | — | — | 2,210,000 | 2,210,000 |
| 41 Moore Drive | |||||||
| Mega Campus: Alexandria Center® for NextGen Medicines/ Research Triangle | 100% | $108,035 | — | — | — | 1,055,000 | 1,055,000 |
| 3029 East Cornwallis Road | |||||||
| Refer to “Mega campus” under “Definitions and reconciliations” in Item 2 for additional information. (1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to “Investments in real estate” under “Definitions and reconciliations” in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties. (2)We have a 100% interest in 601 and 701 Dexter Avenue North aggregating 415,977 RSF and a 60% interest in the priority anticipated development project at 800 Mercer Street aggregating 869,000 RSF. |
72
New Class A/A+ development and redevelopment properties: summary of pipeline (continued)
| Market Property/Submarket Research Triangle (continued) | Our Ownership Interest Under Construction | Book Value Development and Redevelopment Active and Near-Term Construction Committed Near Term | Square Footage Future Opportunities Subject to Market Conditions and Leasing Priority Anticipated | Future | Total(1) | ||||
|---|---|---|---|---|---|---|---|---|---|
| Mega Campus: Alexandria Center® for Sustainable Technologies/Research Triangle | 100% | $53,326 | — | — | — | 750,000 | 750,000 | ||
| 120 TW Alexander Drive, 2752 East NC Highway 54, and 10 South Triangle Drive | |||||||||
| 100 Capitola Drive/Research Triangle | 100% | — | — | — | — | 65,965 | 65,965 | ||
| Other development and redevelopment projects | 100% | 4,185 | — | — | — | 76,262 | 76,262 | ||
| 445,723 | — | — | 180,000 | 5,147,227 | 5,327,227 | ||||
| New York City | |||||||||
| Mega Campus: Alexandria Center® for Life Science – New York City/New York City | 100% | 165,061 | — | — | — | 550,000 | (2) | 550,000 | |
| 165,061 | — | — | — | 550,000 | 550,000 | ||||
| Texas | |||||||||
| Alexandria Center® for Advanced Technologies at The Woodlands/ Greater Houston | 100% | 49,034 | 73,298 | — | — | 116,405 | 189,703 | ||
| 8800 Technology Forest Place | |||||||||
| 1001 Trinity Street and 1020 Red River Street/Austin | 100% | 10,177 | — | — | 126,034 | 123,976 | 250,010 | ||
| Other development and redevelopment projects | 100% | 136,980 | — | — | — | 1,694,000 | 1,694,000 | ||
| 196,191 | 73,298 | — | 126,034 | 1,934,381 | 2,133,713 | ||||
| Canada | 100% | 50,044 | 139,311 | — | — | 371,743 | 511,054 | ||
| Other development and redevelopment projects | 100% | 120,411 | — | — | — | 724,349 | 724,349 | ||
| Total pipeline as of September 30, 2024 | $9,340,425 | (3) | 4,975,327 | 492,570 | 2,163,784 | 27,582,766 | 35,214,447 |
Refer to “Mega campus” under “Definitions and reconciliations” in Item 2 for additional information.
(1) Total square footage includes 3,376,039 RSF of buildings currently in operation that we expect to demolish or redevelop and commence future construction subject to market conditions and leasing. Refer to “Investments in real estate”
under “Definitions and reconciliations” in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties.
(2) During the three months ended September 30, 2024, we filed a lawsuit against the New York City Health + Hospitals Corporation and the New York City Economic Development Corporation for fraud and breach of contract concerning our
option to ground lease a land parcel to develop a future world-class life science building within the Alexandria Center® for Life Science – New York City campus. Refer to “Legal proceedings” in Item 1 under Part II – Other Information for
additional details.
(3) Includes $4.3 billion of projects that are currently under construction and are 55% leased/negotiating. We also expect to commence construction of one committed near-term project aggregating $69.5 million, which is 51% leased/
negotiating, in the next two years after September 30, 2024.
73
Results of operations
We present a tabular comparison of items, whether gain or loss, that may facilitate a high-level understanding of our results
and provide context for the disclosures included in our annual report on Form 10-K for the year ended December 31, 2023 and our
subsequent quarterly reports on Form 10-Q. We believe that such tabular presentation promotes a better understanding for investors of
the corporate-level decisions made and activities performed that significantly affect comparison of our operating results from period to
period. We also believe that this tabular presentation will supplement for investors an understanding of our disclosures and real estate
operating results. Gains or losses on sales of real estate and impairments of assets classified as held for sale are related to corporate-
level decisions to dispose of real estate. Gains or losses on early extinguishment of debt are related to corporate-level financing
decisions focused on our capital structure strategy. Significant realized and unrealized gains or losses on non-real estate investments,
impairments of real estate and non-real estate investments, and acceleration of stock compensation expense due to the resignations of
executive officers are not related to the operating performance of our real estate assets as they result from strategic, corporate-level
non-real estate investment decisions and external market conditions. Impairments of non-real estate investments are not related to the
operating performance of our real estate as they represent the write-down of non-real estate investments when their fair values
decrease below their respective carrying values due to changes in general market or other conditions outside of our control. Significant
items, whether a gain or loss, included in the tabular disclosure for current periods are described in further detail in Item 2. Key items
included in net income attributable to Alexandria’s common stockholders for the three and nine months ended September 30, 2024 and
2023 and the related per share amounts were as follows (in millions, except per share amounts):
| Three Months Ended September 30, 2024 Amount | 2023 | 2024 Per Share – Diluted | 2023 | Nine Months Ended September 30, 2024 Amount | 2023 | 2024 Per Share – Diluted | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Unrealized gains (losses) on non-real estate investments | $2.6 | $(77.2) | $0.02 | $(0.45) | $(32.5) | $(221.0) | $(0.19) | $(1.29) |
| Gain on sales of real estate | 27.1 | — | 0.16 | — | 27.5 | 214.8 | 0.16 | 1.26 |
| Impairment of non-real estate investments | (10.3) | (28.5) | (0.06) | (0.17) | (37.8) | (51.5) | (0.22) | (0.30) |
| Impairment of real estate | (5.7) | (20.6) | (0.03) | (0.12) | (36.5) | (189.2) | (0.22) | (1.11) |
| Acceleration of stock compensation expense due to executive officer resignations | — | (1.9) | — | (0.01) | — | (1.9) | — | (0.01) |
| Total | $13.7 | $(128.2) | $0.09 | $(0.75) | $(79.3) | $(248.8) | $(0.47) | $(1.45) |
Refer to Note 3 – “Investments in real estate” and Note 7 – “Investments” to our unaudited consolidated financial statements in
Market risk
As filed, 5,353 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Interest rate risk
The primary market risk to which we believe we may be exposed is interest rate risk, which may result from many factors,
including government monetary and tax policies, domestic and international economic and political considerations, and other factors
that are beyond our control.
In order to modify and manage the interest rate characteristics of our outstanding debt and to limit the effects of interest rate
risks on our operations, we may utilize a variety of financial instruments, including interest rate hedge agreements, caps, floors, and
other interest rate exchange contracts. The use of these types of instruments to hedge a portion of our exposure to changes in interest
rates may carry additional risks, such as counterparty credit risk and the legal enforceability of hedge agreements. As of September 30,
2024, we did not have any outstanding interest rate hedge agreements.
Our future earnings and fair values relating to our outstanding debt are primarily dependent upon prevalent market rates of
interest. The following tables illustrate the effect of a 1% change in interest rates, assuming a zero percent interest rate floor, on our
fixed- and variable-rate debt as of September 30, 2024 (in thousands):
| Annualized effect on future earnings due to variable-rate debt: | |
|---|---|
| Rate increase of 1% | $(1,166) |
| Rate decrease of 1% | $1,166 |
| Effect on fair value of total consolidated debt: | |
| Rate increase of 1% | $(824,796) |
| Rate decrease of 1% | $945,937 |
These amounts are determined by considering the effect of the hypothetical interest rates on our borrowings as of
September 30, 2024. These analyses do not consider the effects of the reduced level of overall economic activity that could exist in
such an environment. Furthermore, in the event of a change of such magnitude, we would consider taking actions to further mitigate our
exposure to the change. Because of the uncertainty of the specific actions that would be taken and their possible effects, the sensitivity
analyses assume no changes in our capital structure.
Equity price risk
We have exposure to equity price market risk because we hold equity investments in publicly traded companies and privately
held entities. All of our investments in actively traded public companies are reflected in our consolidated balance sheets at fair value.
Our investments in privately held entities that report NAV per share are measured at fair value using NAV as a practical expedient to fair
value. Our equity investments in privately held entities that do not report NAV per share are measured at cost less impairments,
adjusted for observable price changes during the period. Changes in fair value of public investments, changes in NAV per share
reported by privately held entities, and observable price changes of privately held entities that do not report NAV per share are
classified as investment income in our consolidated statements of operations. There is no assurance that future declines in value will
not have a material adverse effect on our future results of operations. The following table illustrates the effect that a 10% change in the
value of our equity investments would have on earnings as of September 30, 2024 (in thousands):
| Equity price risk: | |
|---|---|
| Fair value increase of 10% | $151,933 |
| Fair value decrease of 10% | $(151,933) |
114
Foreign currency exchange rate risk
We have exposure to foreign currency exchange rate risk related to our subsidiaries operating in Canada. The functional
currencies of our foreign subsidiaries are the local currencies in each respective country. Gains or losses resulting from the translation
of our foreign subsidiaries’ balance sheets and statements of operations are classified in accumulated other comprehensive income
(loss) as a separate component of total equity and are excluded from net income (loss). Gains or losses will be reflected in our
consolidated statements of operations when there is a sale or partial sale of our investment in these operations or upon a complete or
substantially complete liquidation of the investment. The following tables illustrate the effect that a 10% change in foreign currency rates
relative to the U.S. dollar would have on our potential future earnings and on the fair value of our net investment in foreign subsidiaries
based on our current operating assets outside the U.S. as of September 30, 2024 (in thousands):
| Effect on potential future earnings due to foreign currency exchange rate: | |
|---|---|
| Rate increase of 10% | $223 |
| Rate decrease of 10% | $(223) |
| Effect on the fair value of net investment in foreign subsidiaries due to foreign currency exchange rate: | |
| Rate increase of 10% | $40,407 |
| Rate decrease of 10% | $(40,407) |
The sensitivity analyses assume a parallel shift of all foreign currency exchange rates with respect to the U.S. dollar; however,
foreign currency exchange rates do not typically move in such a manner, and actual results may differ materially.
Our exposure to market risk elements for the nine months ended September 30, 2024 was consistent with the risk elements
presented above, including the effects of changes in interest rates, equity prices, and foreign currency exchange rates.
Controls and procedures
As filed, 979 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of disclosure controls and procedures
As of September 30, 2024, we had performed an evaluation, under the supervision of our principal executive officers and
principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures. These controls and
procedures have been designed to ensure that information required for disclosure is recorded, processed, summarized, and reported
within the requisite time periods. Based on our evaluation, the principal executive officers and principal financial officer concluded that
our disclosure controls and procedures were effective as of September 30, 2024.
Changes in internal control over financial reporting
There has not been any change in our internal control over financial reporting during the three months ended September 30,
2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
115
Risk factors
As filed, 4,107 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
In addition to the information set forth in this quarterly report on Form 10-Q, one should also carefully review and consider the
information contained in the other reports and periodic filings that we make with the SEC, including, without limitation, the information
contained under the caption “Item 1A. Risk factors” in our annual report on Form 10-K for the year ended December 31, 2023. Those
risk factors could materially affect our business, financial condition, and results of operations. The risks that we describe in our public
filings are not the only risks that we face. Additional risks and uncertainties not currently known to us, or that we presently deem to be
immaterial, also may materially adversely affect our business, financial condition, and results of operations.
There have been no material changes in our risk factors from those disclosed under the caption “Item 1A. Risk factors” in our
annual report on Form 10-K for the year ended December 31, 2023, except for the following updates:
The increased use of artificial intelligence (“AI”) and automation in life science research and development
(“R&D”) activities may change the uses, space configurations and tenant requirements for our laboratory properties
in currently unforeseen ways.
In recent years, some life science companies have augmented their traditional laboratory-based R&D efforts by
integrating AI, cloud computing, quantum computing and other advanced computational technologies into their R&D programs.
It is expected that such technologies will accelerate and streamline a number of R&D functions, including, for example, through
the targeted design and evaluation of clinical trials and the efficient identification of the most promising drug development
candidates from among multiple possible drugs. In addition, life science companies, like companies in many other industries,
are increasingly integrating new technologies, such as robotics and advanced automation of recurring tasks, into their
businesses, including their R&D activities. It is widely thought that the life science and healthcare industries, like most
industries, are in only the early stages of an advanced technology revolution that may have profound, and largely currently
unknown, impacts on their businesses, including the processes and strategies underlying R&D and commercialization of new
products.
We have always strived to provide our tenants with state-of-the-art laboratory facilities incorporating cutting-edge
infrastructure features (including energy delivery, environmental, sustainability, security, and waste disposal features) to enable
our tenants to perform at the highest levels. It is currently unknown how the ongoing adoption of advanced technologies and
automation in the life science industry will impact the optimal space configurations and infrastructure features of the “laboratory
of the future,” and we may face new tenant requirements and requests that will require significant expenditures that may not be
entirely recoverable through increased rents. For example, the adoption of AI by our tenants may lead to infrastructure
requirements that our buildings currently do not accommodate, such as increased power needs due to high-performance
computing. Infrastructure upgrades may necessitate substantial capital expenditures and could potentially impact the
environmental footprint of our building operations.
116
If technological developments result in a reduction or reconfiguration in space requirements by our tenants, demand by
individual tenants and prospective tenants for space may decrease over time. If we are not able to offset any reduction in demand from
the foregoing developments through repurposing space, property dispositions, or other means, the realization of any of the
aforementioned risks could have a material adverse impact on our revenues, net operating income, results of operations, funds from
operations, operating margins, occupancy, earnings per share, FFO per share, our overall business, and the market value of our
common stock.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-07-01 to 2024-09-30 | $791.6m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 9 months2024-01-01 to 2024-09-30 | $2.33bn | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Interest expense | 3 months2024-07-01 to 2024-09-30 | $43.5m | us-gaap:InterestExpense |
| Interest expense | 9 months2024-01-01 to 2024-09-30 | $130.2m | us-gaap:InterestExpense |
| Net income | 3 months2024-07-01 to 2024-09-30 | $167.9m | us-gaap:NetIncomeLoss |
| Net income | 9 months2024-01-01 to 2024-09-30 | $385.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-07-01 to 2024-09-30 | $0.96 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2024-01-01 to 2024-09-30 | $2.18 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-07-01 to 2024-09-30 | $0.96 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2024-01-01 to 2024-09-30 | $2.18 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-07-01 to 2024-09-30 | 172,058,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2024-01-01 to 2024-09-30 | 172,007,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2024-01-01 to 2024-09-30 | $1.23bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Dividends paid | 9 months2024-01-01 to 2024-09-30 | $671.4m | us-gaap:PaymentsOfDividendsCommonStock |
| Cash and equivalents | At period end2024-09-30 | $562.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Total assets | At period end2024-09-30 | $38.49bn | us-gaap:Assets |
| Total liabilities | At period end2024-09-30 | $15.78bn | us-gaap:Liabilities |
| Long-term debt | At period end2024-09-30 | $12.69bn | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2024-09-30 | $18.22bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001035443-24-000298. Last ingested by Listed: Nov 3, 2026, 21:07 ET. Listed shows no prices and gives no investment advice.